Clinical Trials Logo

Episodic Migraine clinical trials

View clinical trials related to Episodic Migraine.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT06004388 Active, not recruiting - Migraine Clinical Trials

Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C)

Start date: July 21, 2023
Phase: Phase 3
Study type: Interventional

Randomized study of two digital therapeutics for the prevention of episodic migraine in patients currently receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy

NCT ID: NCT05853900 Active, not recruiting - Migraine Clinical Trials

Study of Two Digital Therapeutics for the Prevention of Episodic Migraine

ReMMi-D
Start date: March 28, 2023
Phase: Phase 3
Study type: Interventional

Randomized study of two digital therapeutics for the prevention of episodic migraine

NCT ID: NCT05207865 Active, not recruiting - Migraine Clinical Trials

Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention

Start date: March 15, 2022
Phase: Phase 4
Study type: Interventional

The purpose of this study is to further evaluate the long-term safety and tolerability of daily dosing of rimegepant for the prevention of episodic migraine.

NCT ID: NCT05028569 Active, not recruiting - Episodic Migraine Clinical Trials

Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine

Start date: November 5, 2021
Phase: Phase 3
Study type: Interventional

Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound (ICHD 2018). Migraine can be further categorized according to the frequency of attacks as episodic migraine (EM) or chronic migraine (CM). This study will assess the effects of BOTOX in preventing migraine in adult participants with EM. BOTOX is being developed for the prevention of migraine in adults with episodic migraine (EM). Participants will be enrolled in 3 different treatment groups. There is 1 in 3 chance that participants will be assigned to receive placebo. Approximately 777 adult participants with EM will be enrolled in approximately 125 sites across the world. Participants will receive intramuscular injections (injected into the muscle) of BOTOX or Placebo on Week 0 and Week 12. Eligible participants will receive BOTOX on Week 24 and Week 36. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

NCT ID: NCT04686136 Active, not recruiting - Chronic Migraine Clinical Trials

A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine

Start date: February 19, 2021
Phase: Phase 3
Study type: Interventional

This study will evaluate the Long-Term Safety and Tolerability of Atogepant 60 mg daily for the Prevention of Migraine in Participants with Chronic or Episodic Migraine

NCT ID: NCT04437433 Active, not recruiting - Chronic Migraine Clinical Trials

A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine

Start date: June 18, 2020
Phase: Phase 3
Study type: Interventional

This study will evaluate the long-term safety, efficacy and tolerability of atogepant 60 mg daily for the prevention of migraine in Japanese participants with chronic or episodic migraine.